Skip to main content

Table 2 (abstract P70). Overview of adverse events.

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  

Galcanezumab

Event

Placebo

N=1451

n (%)

120-mg

N=705

n (%)

240-mg

N=730

n (%)

Combined

N=1435

n (%)

Deaths

0

0

0

0

SAE

14 (1.0)

12 (1.7)

11 (1.5)

23 (1.6)

DCAE

24 (1.7)

13 (1.8)

22 (3.0)†

35 (2.4)

TEAE

827 (57.0)

441 (62.6)†

472 (64.7)‡

913 (63.6)‡

  1. Abbreviations: SAE Serious adverse events, DCAE discontinuation due to an adverse event, TEAE Treatment-emergent adverse events
  2. †Indicates P < .05 compared with placebo
  3. ‡Indicates P < .001 compared with placebo
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us